Literature DB >> 19195212

[A case of small cell lung cancer with dermatomyositis that deteriorated with leukocytopenia due to chemotherapy].

Takanori Numata1, Ayako Kawabata, Yu Fujita, Keiko Bono, Kumi Tamura, Jiro Mikami, Hiroshi Wakui, Saburo Ito, Yoko Yumino, Makoto Kawaishi, Kazuyoshi Kuwano.   

Abstract

A 64-year-old woman presented skin lesions on her face, upper extremities and finger erythema (heliotropism and Gottron's sign). She had weakness in her lower extremities. She was given a diagnosis of dermatomyositis (DM), because the serum examination showed that a myositis-specific antibody was positive whereas Jo-1 antibody was negative. The findings of chest X-ray and computed tomography showed that she had limited small cell lung cancer, but no interstitial pneumonia. She was treated with standard chemotherapy consisting of cisplatin and etoposide with accelerated hyperfractionation radiotherapy. She showed partial response to the treatment, whereas the skin lesions and muscle weakness deteriorated accompanied with bone marrow suppression due to chemotherapy. Skin and muscle biopsy were performed and pathological findings showed typical perivasculitis infiltrated with lymphocytes in muscle and skin. With the recovery of bone marrow suppression and partial response due to chemotherapy, the skin lesions improved and creatine kinase became normalized. She was given a diagnosis of paraneoplastic DM. Since severe leukocytopenia paralleled the deterioration of DM, the decrease of peripheral white blood cell counts, especially regulatory T cell counts, may be associated with DM activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19195212

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  1 in total

1.  Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report.

Authors:  Andrew J Beel; David S Demos; Alfred Chung; Charles Liao; Natalie S Lui
Journal:  J Cardiothorac Surg       Date:  2018-02-07       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.